Search

 
 
 
Manufacturing Issues Stall Tesaro Cancer Nausea Drug at FDA

MANUFACTURING ISSUES STALL TESARO CANCER NAUSEA DRUG AT FDA

Manufacturing problems have held back several drugs from FDA approval, and the latest example is a Tesaro drug developed to ease nausea...

 
 
 
Pain Drug Developer Adynxx Picks Up $16M for Another Clinical Trial

PAIN DRUG DEVELOPER ADYNXX PICKS UP $16M FOR ANOTHER CLINICAL TRIAL

Despite the wide range of pain relievers available, many patients find these drugs fall short of easing pain after surgery and during...

 
 
 
Guinea trial shows "historic" success for Ebola vaccine

GUINEA TRIAL SHOWS "HISTORIC" SUCCESS FOR EBOLA VACCINE

A vaccine developed by Merck is the first shown to be highly effective in preventing human infection with Ebola, according to final...

Product Manager - Farm Animal Business Unit

PRODUCT MANAGER - FARM ANIMAL BUSINESS UNIT

Merck Canada Inc. Product Manager - Farm Animal Business Unit Reference number: PRO014986 Location: Montreal , Quebec Employee Status:...

 
 
 
Biogen Promotes Vounatsos to CEO, Capping Scangos' 6-Year Run

BIOGEN PROMOTES VOUNATSOS TO CEO, CAPPING SCANGOS' 6-YEAR RUN

Biogen didn't go far to find its new CEO. The company promoted chief commercial officer Michel Vounatsos to the top spot on Monday,...

 
 
 

MERCK KGAA, DARMSTADT, GERMANY'S PHASE IIB ADDRESS II RESULTS CONFIRM POTENTIAL OF ATACICEPT AS A CANDIDATE THERAPY FOR SLE

Life Sciences Jobs ...

 
 
 

WITH BRISTOL-MYERS SQUIBB, GENENTECH AND MERCK & CO. EXPANDING IN THE BAY AREA, SOME WONDER IF THE REAL ESTATE BOOM IS TOO MUCH

Life Sciences Jobs ...

MERCK KGAA OPENS $189 MILLION NANTONG PHARMA PLANT; PLANS $89 MILLION LIFE SCIENCE CENTER

Life Sciences Jobs ...

 
 
 
Could THIS cure Alzheimer's? New drug found to reduce plaques in the brain

COULD THIS CURE ALZHEIMER'S? NEW DRUG FOUND TO REDUCE PLAQUES IN THE BRAIN

Verubecestat, made by US-based drug giant Merck, reduces levels of beta-amyloid, a protein fragment that accumulates in sticky deposits...

 
 
 
 
 
 
Merck raises its full-year forecast because one drug has been crushing it

MERCK RAISES ITS FULL-YEAR FORECAST BECAUSE ONE DRUG HAS BEEN CRUSHING IT

Thomson Reuters Merck & Co Inc reported a better-than-expected quarterly revenue, driven primarily by higher demand for its new cancer...